Development Challenges for Complex Protein Biologics
Summary: Single-agent therapies may not always be successful in treating complex diseases for which drug resistance is a problem, such as cancer. A combination drug therapy consisting of molecules that modulate multiple targets may be needed to achieve the best possible outcome. The ability to use a single product versus multiple medications greatly simplifies the treatment process, theoretically streamlines manufacturing and potentially improves the patient experience. Pharmaceutical Technology sat down with Dr. Gregory Bleck, Vice President of Research and Development at Catalent Biologics, to discuss factors that drive the emergence of complex, protein-based biologics, areas in which these molecules are experiencing the fastest growth, and challenges in their development and advancement to the clinic.